Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/14581
Title: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial
Authors: Arunee Sabchareon
Derek Wallace
Chukiat Sirivichayakul
Kriengsak Limkittikul
Pornthep Chanthavanich
Saravudh Suvannadabba
Vithaya Jiwariyavej
Wut Dulyachai
Krisana Pengsaa
T. Anh Wartel
Annick Moureau
Melanie Saville
Alain Bouckenooghe
Simonetta Viviani
Nadia G. Tornieporth
Jean Lang
Mahidol University
Asia-Pacific Clinical Development
Thailand Ministry of Public Health
Ratchaburi Regional Hospital
Asia-Pacific Clinical Development
Sanofi Pasteur
Global Clinical RandD Department
Keywords: Medicine
Issue Date: 1-Nov-2012
Citation: The Lancet. Vol.380, No.9853 (2012), 1559-1567
Abstract: Background: Roughly half the world's population live in dengue-endemic countries, but no vaccine is licensed. We investigated the efficacy of a recombinant, live, attenuated tetravalent dengue vaccine. Methods: In this observer-masked, randomised, controlled, monocentre, phase 2b, proof-of-concept trial, healthy Thai schoolchildren aged 4-11 years were randomly assigned (2:1) to receive three injections of dengue vaccine or control (rabies vaccine or placebo) at months 0, 6, and 12. Randomisation was by computer-generated permuted blocks of six and participants were assigned with an interactive response system. Participants were actively followed up until month 25. All acute febrile illnesses were investigated. Dengue viraemia was confirmed by serotype-specific RT-PCR and non-structural protein 1 ELISA. The primary objective was to assess protective efficacy against virologically confirmed, symptomatic dengue, irrespective of severity or serotype, occurring 1 month or longer after the third injection (per-protocol analysis). This trial is registered at ClinicalTrials.gov, NCT00842530. Findings: 4002 participants were assigned to vaccine (n=2669) or control (n=1333). 3673 were included in the primary analysis (2452 vaccine, 1221 control). 134 cases of virologically confirmed dengue occurred during the study. Efficacy was 30·2 (95 CI -13·4 to 56·6), and differed by serotype. Dengue vaccine was well tolerated, with no safety signals after 2 years of follow-up after the first dose. Interpretation: These data show for the first time that a safe vaccine against dengue is possible. Ongoing large-scale phase 3 studies in various epidemiological settings will provide pivotal data for the CYD dengue vaccine candidate. Funding: Sanofi Pasteur. © 2012 Elsevier Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84868211668&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/14581
ISSN: 1474547X
01406736
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.